UK Intellectual Property Office allows patent for polymorph of entinostat

[News]

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced the UK Intellectual Property Office allowed application GB0907347.9 entitled N-(2-aminophenyl)-4-[N-(pyridine-3-YL)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B.

More... (http://www.news-medical.net/news/20101018/UK-Intellectual-Property-Office-allows-patent-for-polymorph-of-entinostat.aspx)